Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cypher versus taxus: are there differences?

Sigmund Silber1

  • 1Cardiology Practice and Hospital, Munich, Germany. sigmund@silber.com

Journal of Interventional Cardiology
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and tolerability of pharmacologic stress with the selective A<sub>2A</sub> adenosine receptor agonist regadenoson for the assessment of myocardial ischemia: results from 5780 consecutive patients in a cardiology practice.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

MMW Fortschritte der Medizin·2026
Same author

[Is the distinction between primary and secondary prevention still relevant today?]

MMW Fortschritte der Medizin·2026
Same author

[Unexplained syncope and congenital long QT syndrome].

MMW Fortschritte der Medizin·2026
Same author

Nuclear cardiology - Current status of the clinical application.

Nuklearmedizin. Nuclear medicine·2026
Same author

MMW Fortschritte der Medizin·2025
Same journal

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease.

Journal of interventional cardiology·2024
Same journal

Effect of Neutrophil-to-Lymphocyte Ratio on Post-TAVR Mortality and Periprocedural Pulmonary Hypertension.

Journal of interventional cardiology·2024
Same journal

Examining the Outcomes of Hybrid Coronary Revascularization in Acute STEMI Patients from 2015 to 2022.

Journal of interventional cardiology·2024
Same journal

Clinical and Laboratory Predictors of Long-Term Outcomes after Catheter Ablation for a Ventricular Electrical Storm.

Journal of interventional cardiology·2024
Same journal

Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial.

Journal of interventional cardiology·2024
Same journal

Mitral Valve Transcatheter Edge-to-Edge Repair Volumes and Trends.

Journal of interventional cardiology·2023
See all related articles

Drug-eluting stents (DES) are standard, but direct comparisons between Cypher and Taxus stents are limited. Current evidence suggests Cypher and Taxus stents are clinically equivalent due to insufficient data for superiority claims.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Drug-eluting stents (DES) are the current standard for stenting procedures in the USA and Switzerland.
  • Numerous DES types are available, releasing various drugs like Paclitaxel, Sirolimus, Everolimus, Biolimus A9, and Zotarolimus.
  • Assessing the clinical relevance and comparative efficacy of different DES is crucial for patient outcomes.

Purpose of the Study:

  • To review published clinically relevant data on drug-eluting stents (DES).
  • To determine if a clinically relevant difference exists between the Cypher and Taxus stent models.
  • To evaluate the evidence supporting the efficacy of various DES based on established criteria.

Main Methods:

  • Systematic review and analysis of 22 randomized controlled trials (RCTs) involving 11,118 patients.

Related Experiment Videos

  • Comparison of DES versus bare metal stents (18 studies, 8,301 patients).
  • Direct comparison of Cypher versus Taxus stents (4 studies, 2,817 patients).
  • Analysis of studies based on drug-eluting agents (Paclitaxel, Sirolimus, Everolimus, etc.) and stent design (polymer-based vs. non-polymer).
  • Evaluation of study endpoints, focusing on clinical outcomes versus surrogate endpoints.

    • Main Results:

    • Eighteen studies compared DES to bare metal stents, showing positive clinical outcomes in trials with adequate power for Taxus, Cypher, and Endeavor stents.
    • Four studies directly compared Cypher and Taxus stents, with methodological limitations including undefined primary endpoints or reliance on surrogate endpoints.
    • Only three DES (Cypher, Taxus, Endeavor) have demonstrated proven positive effects on clinical outcomes according to strict European Society of Cardiology criteria.
    • No multicenter trial with adequate power and a clinical primary endpoint has proven the superiority of one DES over another.

    Conclusions:

    • Based on current evidence, Cypher and Taxus stents are considered clinically equivalent.
    • Further multicenter trials with robust clinical endpoints are required to establish superiority between different DES.
    • The selection of DES should consider established efficacy and safety data, adhering to stringent clinical criteria.